Results 41 to 50 of about 5,546 (214)

Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences

Drugs in Context
Pasireotide-LAR is recommended as a second-line treatment for patients with acromegaly. Although the effects of pasireotide-LAR have been well characterized in clinical studies, real-practice evidence is scant, especially in the long term and within the ...
Sabrina Chiloiro, Marialuisa Appetecchia, Antonio Bianchi, Denise Costa, Christine De Acetis, Patrizia Gargiulo, Antonella Giampietro, Andrea M Isidori, Marie-Lise Jaffrain-Rea, Marina Passeri, Francesca Pigliaru, Maurizio Poggi, Laura De Marinis   +12 more
doaj   +1 more source

Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment

Clinical Case Reports, 2020
Pasireotide improves hypercortisolemia and induces hyperglycemia via somatostatin receptor type‐5 stimulation. GLP‐1RA and SGLT2 inhibitor potentially help regulate hyperglycemia in patients with Cushing's disease, especially after pasireotide ...
Masato Shikata, Kenji Ashida, Yuka Goto, Ayako Nagayama, Shimpei Iwata, Mamiko Yano, Nao Hasuzawa, Kento Hara, Kazutoshi Mawatari, Kiyohiko Sakata, Munehisa Tsuruta, Nobuhiko Wada, Masatoshi Nomura   +12 more
doaj   +1 more source

Antiparallel β‐Sheet as a Key Motif of Amyloid‐β Inhibitor Designed via Topological Peptide Reprogramming

Angewandte Chemie, Volume 137, Issue 28, July 7, 2025.
Targeting Amyloid‐β (Aβ) aggregation requires a peptide‐based approach that accounts for the structural heterogeneity of Aβ. Here, we employ topological reprogramming via disulfide bonds to stabilize antiparallel β‐sheets within the dimeric peptide.
Dongjoon Im, Ye Eun Lee, Gyusub Yoon, William A. Goddard III, Tae Su Choi, Hugh I. Kim   +5 more
wiley   +2 more sources

Pasireotide in an insulin-requiring diabetic acromegalic patient without worsening of hyperglycemia

Endocrinology, Diabetes & Metabolism Case Reports, 2017
Long-acting pasireotide is an effective treatment option for acromegaly, but it is associated with hyperglycemia, which could impact its use in patients with diabetes.
Murray B Gordon, Kellie L Spiller
doaj   +1 more source

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs

Frontiers in Endocrinology, 2020
Introduction: Acromegaly is a rare, serious endocrine disorder characterized by excess growth hormone (GH) secretion by a pituitary adenoma and overproduction of insulin-like growth factor I (IGF-I).
Mônica Gadelha, Marie Bex, Annamaria Colao, Elier Mitsael Pedroza García, Catalina Poiana, Marisela Jimenez-Sanchez, Serkan Yener, Rishav Mukherjee, Amy Bartalotta, Ricardo Maamari, Gérald Raverot   +10 more
doaj   +1 more source

Emerging drugs for Cushing's disease [PDF]

, 2015
INTRODUCTION: Considering the effects of uncontrolled hypercortisolism on morbidity and mortality, there is a clear need for effective medical therapy for patients with Cushing's disease (CD).
Grossman, AB, Guelho, DL
core   +1 more source

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients

Endocrine Connections, 2019
Acromegaly is a rare disease due to chronic excess growth hormone (GH) and IGF-1. Aryl hydrocarbon receptor interacting protein (AIP) mutations are associated with an aggressive, inheritable form of acromegaly that responds poorly to SST2-specific ...
Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ, Albert Beckers   +10 more
doaj   +1 more source

Diabetes mellitus secondary to Cushing's disease [PDF]

, 2018
Associated with important comorbidities that significantly reduce patients’ overall wellbeing and life expectancy, Cushing’s disease (CD) is the most common cause of endogenous hypercortisolism.
Barbot, Mattia, Ceccato, Filippo, Scaroni, Carla   +2 more
core   +2 more sources

Esophageal Perforation in Zollinger–Ellison Syndrome: A Scoping Review of Management and Outcomes

JGH Open, Volume 10, Issue 1, January 2026.
ABSTRACT Esophageal perforation in Zollinger–Ellison syndrome (ZES) is an exceedingly rare and life‐threatening manifestation of gastrinoma‐related acid hypersecretion. While peptic ulceration and severe reflux are recognized complications of ZES, perforation represents the ultimate consequence of uncontrolled hyperacidity. Evidence remains confined to
Agostino Fernicola, Domenico Parmeggiani, Felice Crocetto, Armando Calogero, Alessio Cece, Domenico Romano, Giacomo Benassai, Gennaro Quarto, Michele Santangelo   +8 more
wiley   +1 more source

Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome [PDF]

, 2008
Somatostatin (SS) and dopamine (DA) receptors are widely expressed in neuroendocrine tumours that cause Cushing's Syndrome (CS). Increasing knowledge of specific subtype expression within these tumours and the ability to target these receptor subtypes ...
A Colao, A Colao, A Newman-Tancredi, A Saiardi, A Saveanu, A Saveanu, A Schonbrunn, AB Atkinson, AM Isidori, AM O’Carroll, AS Mahmoud-Ahmed, B Ambrosi, B Ueberberg, C Bruns, C Garcia, C Invitti, C Missale, C Missale, C. de Bruin, D Cervia, D Cervia, D Ferone, D Gaitan, D Morris, D Yin, DC Danila, DL Batista, DN Orth, DW Ray, E Mezey, F Amenta, F Castinetti, F Illouz, F Kelestimur, F Vignati, G Giustina, G Weckbecker, GI Uwaifo, GK Stalla, HA Schmid, HA Schmid, HL Fehm, I Ilias, I Shraga-Slutzky, J Hoek van der, J Hoek van der, J Jagannathan, J Kraicer, J Lindholm, J Newell-Price, J Stack, JB Tyrrell, JC Reubi, JM Farah Jr., JW Miller, KD Wu, L Petrini, L Stefaneanu, L. J. Hofland, LA Casulari, LJ Hofland, LJ Hofland, LJ Hofland, LK Nieman, M Locatelli, M Phlipponneau, M Rocheville, M Tallent, ME Molitch, ML Vance, MR Brown, MZ Strowski, N Unger, N Unger, P Barnett, P Brazeau, P Jaquet, P Jaquet, P Ma, P Petrossians, PJ Stafford, R Day, R Hall, R Pivonello, R Pivonello, R Pivonello, R Pivonello, R Pivonello, R Pivonello, R Pivonello, R Schade, R Zanettini, R. A. Feelders, RJ Benveniste, RJ Croughs, S. W. J. Lamberts, SL Lightman, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, T Antakly, T Miyoshi, UI Richardson, VG Rasmussen, WE Farrell, WW Herder de, WW Herder de, X Bertagna, YC Patel   +115 more
core   +4 more sources